DB
STLN

Dmitry Balyasny’s Starling Oncology STLN Stock Holding History

Dmitry Balyasny’s Portfolio STLN Stock Details STLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,826,370
Closed -$5.61M – 3501
2026
Q1 		$5.61M Sell
1,826,370
-692,067
-27% -$2.12M 0.01% 1325
2025
Q4 		$8.97M Buy
2,518,437
+100
+0% +$371 0.01% 1076
2025
Q3 		$8.79M Hold
2,518,337
– – 0.01% 1118
2025
Q2 		$5.16M Buy
2,518,337
+371,005
+17% +$928K 0.01% 1278
2025
Q1 		$2.45M Buy
2,147,332
+421,770
+24% +$327K ﹤0.01% 1611
2024
Q4 		$533K Hold
1,725,562
– – ﹤0.01% 2175
2024
Q3 		$564K Hold
1,725,562
– – ﹤0.01% 2210
2024
Q2 		$794K Hold
1,725,562
– – ﹤0.01% 1880
2024
Q1 		$2.73M Buy
1,725,562
+472,525
+38% +$898K ﹤0.01% 1447
2023
Q4 		$2.56M Buy
1,253,037
+815,458
+186% +$1.41M ﹤0.01% 1378
2023
Q3 		$613K Buy
+437,579
New +$453K ﹤0.01% 1696
2022
Q2 		– Sell
-10,873
Closed -$78K – 3186
2022
Q1 		$78K Buy
+10,873
New +$73.4K ﹤0.01% 2180

Other funds holding STLN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JAIC
Josh Arnold Investment Consultant Edina, Minnesota $159M AUM 142.62% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
WC
Wexford Capital West Palm Beach, Florida $782M AUM 62.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Dmitry Balyasny's STLN Position: Q2 2026 in Review

Dmitry Balyasny sold out of Starling Oncology (STLN) in Q2 2026, closing a stake of 1,826,370 shares — an estimated $5.61M sold.

Dmitry Balyasny first reported a position in STLN in Q1 2022 and held it in 12 quarters. The position peaked at $8.97M in Q4 2025. 119 funds tracked by Wall St. Rank hold STLN as of Q2 2026.

  • Dmitry Balyasny reported no remaining Starling Oncology position as of Q2 2026 after selling out during the quarter.
  • Dmitry Balyasny sold 1,826,370 Starling Oncology shares in Q2 2026, an estimated $5.61M.
  • Dmitry Balyasny first reported a position in Starling Oncology in Q1 2022 and held it in 12 quarters.
  • Dmitry Balyasny's Starling Oncology position peaked at $8.97M in Q4 2025.
  • 119 funds tracked by Wall St. Rank held Starling Oncology as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.